Peer-Reviewed Publications

      The Apoe−/− mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction

      Lo Sasso, G.; Schlage, W. K.; Boué, S.; Veljkovic, E.; Peitsch, M. C.; Hoeng, J.

      Published
      May 20, 2016
      DOI
      10.1186/s12967-016-0901-1
      PMID
      27207171
      Link to publication
      Topic
      Summary

      Atherosclerosis-prone apolipoprotein E-deficient (Apoe-/-) mice display poor lipoprotein clearance with subsequent accumulation of cholesterol ester-enriched particles in the blood, which promote the development of atherosclerotic plaques. Therefore, the Apoe-/- mouse model is well established for the study of human atherosclerosis. The systemic proinflammatory status of Apoe-/- mice also makes them good candidates for studying chronic obstructive pulmonary disease, characterized by pulmonary inflammation, airway obstruction, and emphysema, and which shares several risk factors with cardiovascular diseases, including smoking. Herein, we review the results from published studies using Apoe-/- mice, with a particular focus on work conducted in the context of cigarette smoke inhalation studies. The findings from these studies highlight the suitability of this animal model for researching the effects of cigarette smoking on atherosclerosis and emphysema.

      Related Publications

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      Novel α7 nicotinic acetylcholine receptor modulators as potential antitussive agents

      Pre-clinical Toxicology

      Differentiating the neuropharmacological properties of nicotinic acetylcholine receptor-activating alkaloids

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.